Logo image of JANX

JANUX THERAPEUTICS INC (JANX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:JANX - US47103J1051 - Common Stock

13.27 USD
+0.12 (+0.91%)
Last: 1/21/2026, 4:04:05 PM
13.27 USD
0 (0%)
After Hours: 1/21/2026, 4:04:05 PM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to JANX. JANX was compared to 525 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for JANX as it has an excellent financial health rating, but there are worries on the profitability. JANX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • JANX had negative earnings in the past year.
  • In the past year JANX has reported a negative cash flow from operations.
  • In the past 5 years JANX always reported negative net income.
  • JANX had a negative operating cash flow in each of the past 5 years.
JANX Yearly Net Income VS EBIT VS OCF VS FCFJANX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -9.94%, JANX belongs to the top of the industry, outperforming 84.00% of the companies in the same industry.
  • JANX has a Return On Equity of -10.43%. This is amongst the best in the industry. JANX outperforms 87.24% of its industry peers.
Industry RankSector Rank
ROA -9.94%
ROE -10.43%
ROIC N/A
ROA(3y)-13.05%
ROA(5y)-17.92%
ROE(3y)-14.45%
ROE(5y)-29.83%
ROIC(3y)N/A
ROIC(5y)N/A
JANX Yearly ROA, ROE, ROICJANX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -1K -2K

1.3 Margins

  • JANX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
JANX Yearly Profit, Operating, Gross MarginsJANX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

More info and screens

8

2. Health

2.1 Basic Checks

  • JANX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for JANX has been increased compared to 1 year ago.
  • Compared to 5 years ago, JANX has more shares outstanding
  • JANX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
JANX Yearly Shares OutstandingJANX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
JANX Yearly Total Debt VS Total AssetsJANX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • JANX has an Altman-Z score of 10.09. This indicates that JANX is financially healthy and has little risk of bankruptcy at the moment.
  • JANX has a better Altman-Z score (10.09) than 82.67% of its industry peers.
  • There is no outstanding debt for JANX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 10.09
ROIC/WACCN/A
WACC8.88%
JANX Yearly LT Debt VS Equity VS FCFJANX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M 1B

2.3 Liquidity

  • A Current Ratio of 35.86 indicates that JANX has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 35.86, JANX belongs to the top of the industry, outperforming 98.86% of the companies in the same industry.
  • JANX has a Quick Ratio of 35.86. This indicates that JANX is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of JANX (35.86) is better than 98.86% of its industry peers.
Industry RankSector Rank
Current Ratio 35.86
Quick Ratio 35.86
JANX Yearly Current Assets VS Current LiabilitesJANX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

  • JANX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -43.59%.
  • The Revenue for JANX has decreased by -23.37% in the past year. This is quite bad
  • The Revenue has been growing by 42.75% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-43.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.53%
Revenue 1Y (TTM)-23.37%
Revenue growth 3Y42.75%
Revenue growth 5YN/A
Sales Q2Q%2177.9%

3.2 Future

  • Based on estimates for the next years, JANX will show a very negative growth in Earnings Per Share. The EPS will decrease by -26.30% on average per year.
  • JANX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 55.14% yearly.
EPS Next Y-59.34%
EPS Next 2Y-52.2%
EPS Next 3Y-43.81%
EPS Next 5Y-26.3%
Revenue Next Year-9.12%
Revenue Next 2Y-64.36%
Revenue Next 3Y-22.51%
Revenue Next 5Y55.14%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
JANX Yearly Revenue VS EstimatesJANX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
JANX Yearly EPS VS EstimatesJANX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for JANX. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for JANX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
JANX Price Earnings VS Forward Price EarningsJANX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
JANX Per share dataJANX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • JANX's earnings are expected to decrease with -43.81% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-52.2%
EPS Next 3Y-43.81%

More info and screens

0

5. Dividend

5.1 Amount

  • JANX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

JANUX THERAPEUTICS INC

NASDAQ:JANX (1/21/2026, 4:04:05 PM)

After market: 13.27 0 (0%)

13.27

+0.12 (+0.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)02-25
Inst Owners106.78%
Inst Owner Change-0.36%
Ins Owners1.45%
Ins Owner Change3.06%
Market Cap798.19M
Revenue(TTM)10.00M
Net Income(TTM)-101.89M
Analysts85.38
Price Target64.01 (382.37%)
Short Float %17.09%
Short Ratio4.35
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)11.26%
Min EPS beat(2)-15.55%
Max EPS beat(2)38.06%
EPS beat(4)3
Avg EPS beat(4)12.66%
Min EPS beat(4)-15.55%
Max EPS beat(4)38.06%
EPS beat(8)6
Avg EPS beat(8)14.06%
EPS beat(12)10
Avg EPS beat(12)18.21%
EPS beat(16)12
Avg EPS beat(16)14.95%
Revenue beat(2)1
Avg Revenue beat(2)67.39%
Min Revenue beat(2)-100%
Max Revenue beat(2)234.78%
Revenue beat(4)1
Avg Revenue beat(4)-16.3%
Min Revenue beat(4)-100%
Max Revenue beat(4)234.78%
Revenue beat(8)4
Avg Revenue beat(8)148.09%
Revenue beat(12)8
Avg Revenue beat(12)153.87%
Revenue beat(16)12
Avg Revenue beat(16)157.29%
PT rev (1m)-7.64%
PT rev (3m)-19.96%
EPS NQ rev (1m)0%
EPS NQ rev (3m)9.72%
EPS NY rev (1m)0.32%
EPS NY rev (3m)12.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)44.44%
Revenue NY rev (1m)0%
Revenue NY rev (3m)252.09%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 79.82
P/FCF N/A
P/OCF N/A
P/B 0.82
P/tB 0.82
EV/EBITDA N/A
EPS(TTM)-1.68
EYN/A
EPS(NY)-2.97
Fwd EYN/A
FCF(TTM)-1.19
FCFYN/A
OCF(TTM)-1.17
OCFYN/A
SpS0.17
BVpS16.24
TBVpS16.24
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -9.94%
ROE -10.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-13.05%
ROA(5y)-17.92%
ROE(3y)-14.45%
ROE(5y)-29.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 47.23%
Cap/Sales 9.79%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 35.86
Quick Ratio 35.86
Altman-Z 10.09
F-Score2
WACC8.88%
ROIC/WACCN/A
Cap/Depr(3y)293.31%
Cap/Depr(5y)445.07%
Cap/Sales(3y)33.73%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-43.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.53%
EPS Next Y-59.34%
EPS Next 2Y-52.2%
EPS Next 3Y-43.81%
EPS Next 5Y-26.3%
Revenue 1Y (TTM)-23.37%
Revenue growth 3Y42.75%
Revenue growth 5YN/A
Sales Q2Q%2177.9%
Revenue Next Year-9.12%
Revenue Next 2Y-64.36%
Revenue Next 3Y-22.51%
Revenue Next 5Y55.14%
EBIT growth 1Y-67.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-62.7%
EBIT Next 3Y-38.69%
EBIT Next 5Y-20.19%
FCF growth 1Y-27.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-33.93%
OCF growth 3YN/A
OCF growth 5YN/A

JANUX THERAPEUTICS INC / JANX FAQ

What is the fundamental rating for JANX stock?

ChartMill assigns a fundamental rating of 4 / 10 to JANX.


What is the valuation status for JANX stock?

ChartMill assigns a valuation rating of 0 / 10 to JANUX THERAPEUTICS INC (JANX). This can be considered as Overvalued.


Can you provide the profitability details for JANUX THERAPEUTICS INC?

JANUX THERAPEUTICS INC (JANX) has a profitability rating of 2 / 10.